NCT00464737View on ClinicalTrials.gov

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.

PHASE2CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Fibromyalgia Syndrome
Interventions
DRUG

Rotigotine

Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)

DRUG

Rotigotine

Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)

OTHER

Placebo

Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.

Trial Locations (35)

10022

New York

27612

Raleigh

32611

Gainesville

32720

DeLand

32806

Orlando

33606

Tampa

44122

Cleveland

45408

Dayton

63141

St Louis

73112

Oklahoma City

85381

Peoria

92705

Santa Ana

98104

Seattle

Unknown

Mobile

Mesa

Fort Myers

Ocala

Palm Beach

Sunrise

Columbia

Stratford

Albuquerque

Rochester

Williamsville

Charlotte

Portland

Souderton

Crossville

Dallas

San Antonio

Bountiful

Richmond

06416

Cromwell

01103

Springfield

05091

Woodstock

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT00464737 - The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. | Biotech Hunter | Biotech Hunter